PHP
ANRO icon

Parkman Healthcare Partners’s Alto Neuroscience ANRO Stock Holding History

Parkman Healthcare Partners’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.3M Buy
+429,035
New +$9.92M 1.16% 35

Other funds holding ANRO

AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Parkman Healthcare Partners's ANRO Position: Q2 2026 in Review

Parkman Healthcare Partners opened a new position in Alto Neuroscience (ANRO) in Q2 2026: 429,035 shares worth $11.3M. The stake represents 1.16% of the portfolio and ranks #35 among its holdings.

114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

  • Parkman Healthcare Partners held 429,035 shares of Alto Neuroscience worth $11.3M as of Q2 2026.
  • Alto Neuroscience was a new Parkman Healthcare Partners position in Q2 2026.
  • Alto Neuroscience made up 1.16% of Parkman Healthcare Partners's portfolio in Q2 2026, its #35 holding.
  • 114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Parkman Healthcare Partners's 13F filing for Q2 2026, filed 14 Aug 2026.